

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

26 May 2026

### Comparison of neuroprotective effects of Memantine-Atorvastatin combination regimen with Atorvastatin in patients with ischemic stroke

#### Protocol summary

2012-12-06, 1391/09/16

#### Summary

The purpose of this study is to compare neuroprotective effects of Atorvastatin with combination of Atorvastatin and Memantine in adult patients with ischemic stroke In this randomized, 2-armed parallel group clinical trial, 40 patients will be recruited from department of neurology, Imam Hussein hospital, Tehran, Iran. After randomization of the subject, subjects in group A will receive Atorvastatin 20mg twice daily and subjects in group B will receive Atorvastatin 20mg twice daily and Memantine 20mg three times daily for 5 days and then 20mg daily for 3 months Primary outcome measures include: Change in matrix metallo-proteinase 2 and -9 from baseline after 3 and 5 days of Atorvastatin compared to combination of Atorvastatin with memantine (time frame: baseline, 3 days and 5 days after intervention) Secondary Outcome Measures: 1- Improvements from baseline scores after 5 days of Atorvastatin compared to combination of Atorvastatin with Memantine on National Institute of Health Stroke Score (time frame: baseline and 5 days after intervention) 2- Improvements from baseline scores after 5 days of Atorvastatin compared to combination of Atorvastatin with Memantine on Barthel index (time frame: baseline, 1 month and 3 months after intervention)

#### Registrant information

##### Name

Mohammad Sistanizad

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8820 0087

##### Email address

sistanizadm@sbmu.ac.ir

#### Recruitment status

##### Recruitment complete

#### Funding source

Shahid Beheshti University of Medical Sciences

#### Expected recruitment start date

2012-10-22, 1391/08/01

#### Expected recruitment end date

2013-03-20, 1391/12/30

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Scientific title

Comparison of neuroprotective effects of Memantine-Atorvastatin combination regimen with Atorvastatin in patients with ischemic stroke

#### Public title

Neuroprotective effects of Memantine in ischemic stroke

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

inclusion criteria: all patients with stroke exclusion criteria: hemorrhagic stroke; sensitivity to Memantine or Statins; acute or chronic renal failure; acute or chronic

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2012092910178N2**

Registration date: **2012-12-06, 1391/09/16**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

hepatic disease; acute MI (<48 hours); autoimmune diseases; administration of Statin or Memantine during 6 months before stroke

#### Age

From **18 years** old

#### Gender

Both

#### Phase

N/A

#### Groups that have been masked

*No information*

#### Sample size

Target sample size: **40**

#### Randomization (investigator's opinion)

Randomized

#### Randomization description

#### Blinding (investigator's opinion)

Not blinded

#### Blinding description

#### Placebo

Not used

#### Assignment

Parallel

#### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Shahid Beheshti University of Medical Sciences

##### Street address

Velenjak Street, Shahid Chamran High Way

##### City

Tehran

##### Postal code

#### Approval date

2012-04-03, 1391/01/15

#### Ethics committee reference number

90-1-94-8104

## Health conditions studied

### 1

#### Description of health condition studied

Stroke

#### ICD-10 code

164

#### ICD-10 code description

Stroke, not specified as haemorrhage or infarction

## Primary outcomes

### 1

#### Description

matrix metaloproteinase 2

#### Timepoint

Day 1, 3, 5

#### Method of measurement

ELISA kits

### 2

#### Description

matrix metaloproteinase 9

#### Timepoint

Day 1, 3, 5

#### Method of measurement

ELISA kits

## Secondary outcomes

### 1

#### Description

Barthel index

#### Timepoint

3 months after ischemic stroke

#### Method of measurement

Questionnaire

### 2

#### Description

mortality

#### Timepoint

90 days after stroke

#### Method of measurement

check by phone

### 3

#### Description

National Institute for Health Stroke Score (NIHSS)

#### Timepoint

Days 1 and 5 after stroke

#### Method of measurement

Questionnaire

## Intervention groups

### 1

#### Description

Intervention: Memantine 20 mg TID plus Atorvastatin 20 mg BID for 5 days then Memantine 10 mg BID and Atorvastatin 40 mg daily for 3 months.

#### Category

Treatment - Drugs

### 2

#### Description

Control: Atorvastatin 20 mg BID for first 5 days and 40 mg daily for 3 months

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Department of Neurology, Imam Hussein Hospital

**Full name of responsible person**

Mohammad Sistanizad

**Street address**

Shahid Madani Street

**City**

Tehran

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Tahereh Shams

**Street address**

Velenjak Street, Shahid Chamran High Way

**City**

Tehran

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector***empty***Domestic or foreign origin***empty***Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding***empty***Person responsible for general inquiries****Contact****Name of organization / entity**

Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Mohammad Sistanizad

**Position**

Assistant Professor / Clinical Pharmacy Specialist

**Other areas of specialty/work****Street address**

Department of Clinical Pharmacy, Faculty of

Pharmacy, Niayesh Highway

**City**

Tehran

**Postal code****Phone**

+98 21 8820 0087

**Fax****Email**

sistanizadm@sbmu.ac.ir

**Web page address****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Mohammad Sistanizad

**Position**

Assistant Professor / Clinical Pharmacy Specialist

**Other areas of specialty/work****Street address**

Department of Clinical Pharmacy, Faculty of Pharmacy, Niayesh Highway

**City**

Tehran

**Postal code****Phone**

+98 21 8820 0087

**Fax****Email**

sistanizadm@sbmu.ac.ir

**Web page address****Person responsible for updating data****Contact****Name of organization / entity**

Department of Clinical Pharmacy, Faculty of Pharmacy, Niayesh Highway

**Full name of responsible person**

Hamidreza Kafi

**Position**

Clinical Pharmacist

**Other areas of specialty/work****Street address**

Department of Clinical Pharmacy, Faculty of Pharmacy, Niayesh Highway

**City**

Tehran

**Postal code****Phone**

+98 21 8820 0087

**Fax****Email**

kafih@yahoo.com

**Web page address**

## **Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*